Skip to Menu Skip to Search Contact Us Skip to Content
US Flag

You are accessing SGS’s website from the USA.

Visit the US website instead

Stay on the global website and remember my choice

Nitrosamines: Questioning the Current Analytical Approach

In recent years, multiple drug products (DPs) have been recalled following the discovery of nitrosamine impurities. Consequently, regulators and the pharmaceutical industry are working hard to identify sources of nitrosamine impurities.

The latest US Food and Drug Administration (FDA) guidance from 2020 lists at least seven potential root causes, while the most recent guidance by the European Medical Agency (EMA) lists eleven. The variety in the possible root causes makes accurate risk assessment a challenging proposition. In this white paper, we look at the challenges posed in regards to testing methodologies and the way in which to move forward to ensure safer DPs.

Please complete the form to download your copy.

Fields marked with an asterisk (*) are mandatory.

White paper request form

Are you an SGS client?*

200 characters remaining